OBJECTIVES: To investigate the clinical significance of miR-335 expression in epithelial ovarian cancer (EOC). METHODS: Expression of miR-335 in normal ovaries, EOC, and omental metastases was determined by quantitative realtime polymerase chain reaction. Overall survival (OS) and relapse-free survival (RFS) were examined using KaplanMeier curves and the Cox proportional hazards regression model. RESULTS: miR-335 expression level was reduced in malignant tissue samples, especially in omental metastases. Low miR-335 levels in EOC were associated with shorter OS (P < .001) and RFS (P = .002). In the multivariate analyses, low miR-335 levels emerged as an independent prognostic factor for poor OS (P = .005) and RFS (P = .016). miR-335 was downregulated in the recurrence group compared with the nonrecurrence group. The area under the receiver operating characteristic curve was 0.818 (95% confidence interval, 0.675-0.961). CONCLUSIONS: Our results indicate that miR-335 relates to the prognosis of patients with EOC and is a promising predictor of EOC recurrence.
OBJECTIVES: To investigate the clinical significance of miR-335 expression in epithelial ovarian cancer (EOC). METHODS: Expression of miR-335 in normal ovaries, EOC, and omental metastases was determined by quantitative realtime polymerase chain reaction. Overall survival (OS) and relapse-free survival (RFS) were examined using KaplanMeier curves and the Cox proportional hazards regression model. RESULTS:miR-335 expression level was reduced in malignant tissue samples, especially in omental metastases. Low miR-335 levels in EOC were associated with shorter OS (P < .001) and RFS (P = .002). In the multivariate analyses, low miR-335 levels emerged as an independent prognostic factor for poor OS (P = .005) and RFS (P = .016). miR-335 was downregulated in the recurrence group compared with the nonrecurrence group. The area under the receiver operating characteristic curve was 0.818 (95% confidence interval, 0.675-0.961). CONCLUSIONS: Our results indicate that miR-335 relates to the prognosis of patients with EOC and is a promising predictor of EOC recurrence.
Authors: Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz Journal: Cell Mol Life Sci Date: 2014-10-09 Impact factor: 9.261